• Moleculin Biotech highlighted encouraging interim results from its pivotal Phase 2/3 MIRACLE trial of Annamycin in relapsed or refractory AML.
• Results have already been presented in a virtual investor “Why Now” on-demand conference.
• Management framed the drug’s profile as differentiated, supporting a potential registration path if upcoming analyses remain supportive.
• Focus now shifts to an upcoming interim readout at 90 patients, positioned as a key catalyst for the program.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moleculin Biotech Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608270901PRIMZONEFULLFEED9816903) on August 27, 2026, and is solely responsible for the information contained therein.